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M
icrobicides are chemical 
agents used topically by 
women within the vagina in 
order to prevent infection by HIV and 
potentially by other enveloped viruses 
and sexually transmitted pathogens. 
Prototype microbicides are designed 
to be inserted prior to each act of 
sexual intercourse and could also be 
contraceptive, although most current 
potential microbicides are not. Several 
proof-of-principle phase III trials of 
candidate microbicides are currently in 
progress or are shortly to commence, 
and a deﬁ  nitive answer to their efﬁ  cacy 
and safety is anticipated by 2008. 
Why Develop Chemical Barriers 
against HIV?
It is the unequivocal experience of 
the 20th century that the control of 
viral infections globally can best be 
achieved through the wide application 
of preventative vaccines. As discussed 
recently in PLoS Medicine, there is to be 
increased coordination and investment 
in a “Global Enterprise” to create an 
AIDS vaccine [1]. Disappointingly, 
however, in spite of much effort and 
investment, there is currently no 
proven vaccine against HIV, and no 
genuinely plausible candidate on the 
horizon. Richard Horton, editor of The 
Lancet, commented recently in the New 
York Review of Books that “one would 
be wise to plan the control of HIV 
infection globally over the next decade 
without assuming that a vaccine will be 
available” [2].
In the absence of a vaccine, novel 
biomedical methods for the prevention 
of HIV transmission assume far greater 
priority. Physical barriers such as 
the condom have been repeatedly 
demonstrated to have a high efﬁ  cacy 
in the prevention of HIV transmission 
during sexual intercourse [3]. 
However, condoms remain almost 
exclusively under the control of the 
male partner, and in many societies 
women simply cannot negotiate 
condom use. A female-controlled 
method to prevent or reduce HIV 
risk is highly desirable, especially as 
this would allow sex education to 
promote mechanisms for both males 
and females, with the potential for an 
additive effect on the reduction of HIV 
transmission if used with a condom or 
other barrier methods. To be successful 
in reducing HIV transmission through 
being widely accepted and available, 
microbicides will need to be proven 
effective in phase III trials, and 
will need to be non-toxic and well 
tolerated, odour-less and colour-less, 
easily administered, and cheap to 
manufacture.
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First-Generation Microbicides: 
Surfactants
The ﬁ  rst vaginal microbicide to be 
studied was nonoxynol-9 (N9), an 
anionic surfactant initially developed in 
the 1960s as a contraceptive spermicide 
with lubricant properties, and latterly 
used extensively to coat latex condoms. 
N9 destroys the integrity of lipid bilayer 
membranes, and so has a virucidal 
action through disrupting the viral 
envelope. 
The antiviral activity of N9 in 
vitro was ﬁ  rst recognised in 1985 
[4]. Evidence of activity in vivo was 
reported by Miller et al. in 1992 [5], 
with local N9 administration leading 
to reduction in transmission of simian 
immunodeﬁ  ciency virus in a vaginal 
challenge macaque model. N9 has an 
IC50 of 2–5 ug/ml for both primary 
and laboratory-adapted HIV-1 strains 
(IC50 is the quantity of a substance 
that reduces HIV infection of cells 
in culture by 50%), and it is active 
against diverse HIV genotypes in 
vitro. However, the antiviral effect 
of N9 is non-speciﬁ  c, with the CC50 
(the quantity of a substance required 
to damage cells in culture such that 
active uptake of tritiated thymidine 
or other biomarkers is reduced by 
50%) and IC50 occurring at similar 
concentrations. 
Early experience in placebo-
controlled ﬁ  eld studies by Joan Kreiss 
et al. in 1992 in Kenya [6] and by Ron 
Roddy et al. in 1998 among commercial 
sex workers in Cameroon [7] suggested 
that N9 may be associated with local 
vaginal toxicity, including ulcerations, 
without clear evidence of efﬁ  cacy 
against HIV transmission. A phase I 
safety study of N9 in healthy women 
volunteers in London showed that 
regular administration of N9 led 
to histological evidence of vaginal 
inﬂ  ammation, including increased 
CD4+ T lymphocytes and macrophages 
[8]. The ﬁ  nal phase III multi-centre 
randomised placebo-controlled trial 
(COL 1492) of N9, undertaken by 
the United Nations Joint Programme 
on HIV/AIDS in 2002, showed that 
N9 had no efﬁ  cacy in preventing 
HIV transmission [9]. Indeed, the 
transmission rate was marginally higher 
in the N9 group, and it was considered 
that this might be related to the local 
vaginal toxicity seen in earlier studies. 
More recently, the company Biosyn 
has developed a new surfactant 
microbicide, SAVVY (Figure 1), 
which is thought to be signiﬁ  cantly 
less cytotoxic than N9 while retaining 
antiviral activity, and which is currently 
in phase III trials in sites in West Africa.   
SAVVY is believed to exert its virucidal 
activity through disruption of the HIV 
envelope lipid bilayer via the same 
mechanism as N9, although the basis 
of its lower cytotoxicity is not reported 
[10].
Second-Generation Microbicides:
Blocking HIV Binding
The problems with N9 strongly 
suggested that for new vaginal 
microbicides to be effective, these 
agents would need to be largely devoid 
of local vaginal toxicity. The ﬁ  rst class 
of agents to be systematically explored 
(in 1992) were agents that blocked 
the binding of HIV-1 to target cells 
in vitro [11]. The anti-HIV activity of 
polyanions had ﬁ  rst been described 
in 1987 [12], but these agents had too 
high a molecular weight to be orally 
absorbed, and interfered with clotting 
if given parenterally, and hence they 
were not developed for antiviral 
therapy. 
Candidate agents in this class (i.e., 
agents that block HIV binding) now 
include several high molecular weight 
anionically charged sulphated polymers 
such as PRO 2000 (a naphthalene 
sulphonate polymer), carageenan (a 
naturally occurring sulphated sugar 
polymer), and cellulose sulphate 
(Figure 1). These three agents have 
potent anti-HIV activity in vitro against 
the two major classes of HIV-1 isolates 
using both the CCR5 and the CXCR4 
co-receptors. Unlike N9, these agents 
have a very low toxicity, and the 
therapeutic index (ratio of CC50 to 
IC50) is above 10,000.
PRO 2000 has been extensively 
studied in vivo in the simian-human 
immunodeﬁ  ciency virus macaque 
vaginal challenge model, with 50%–
90% protection against infection 
depending on experimental conditions 
[13]. The absence of absorption of 
these high molecular weight agents is 
a positive beneﬁ  t for intra-vaginal use, 
as very high local concentrations of 
these polyanions have been shown to 
be tolerable in animal models and in 
human phase II trials [14]. PRO 2000, 
carageenan, and cellulose sulphate are 
all in, or will shortly be in, phase III 
trials in women at risk of HIV infection 
in Africa (see Table 1).
The healthy vagina is maintained 
at low pH and microbially populated 
with hydrogen-peroxide-producing 
lactobacilli. There is some evidence 
that maintenance of this healthy 
vaginal milieu may protect against 
infection by HIV and other sexually 
transmitted infections; all current 
microbicides are buffered to pH 4.5 
in order to promote vaginal health, 
and all have been investigated for their 
ability to sustain vaginal lactobacilli in 
vivo [15]. One candidate microbicide, 
“BufferGel”, whose mechanism of 
action is speciﬁ  cally based on the 
maintenance of a low vaginal pH, is 
being assessed in parallel with PRO 
2000 in a phase IIb trial ([16]; see 
Table 1).
Third-Generation Microbicides:
Topical Antiretrovirals
The polyanions meet many of the 
desirable properties of an ideal 
vaginal microbicide, being cheap 
to manufacture, active in vitro 
and in macaque vaginal challenge 
experiments, and safe and tolerable in 
vivo in phase II trials. However, they 
rely on charge for their effect, and 
they are non-speciﬁ  c for enveloped 
viruses and may all be slightly less 
active against CCR5-using primary 
virus isolates, the major transmitted 
variant of HIV-1. Ongoing phase 
III trials will ultimately determine 
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Figure 1. Sites of Action of Candidate 
Microbicides 
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whether their activity and tolerability 
translate into efﬁ  cacy. It is too 
premature to assume success with 
the second-generation agents, and 
HIV-speciﬁ  c microbicide agents are 
currently being developed in phase I 
and II clinical trials.
Tenofovir, a nucleotide analogue 
reverse transcriptase inhibitor 
antiretroviral drug with a long half-life, 
has been successfully introduced as an 
oral agent for HIV infection. Studies 
of tenofovir in macaques suggest 
that pre-dosing may prevent simian 
immunodeﬁ  ciency virus infection, and 
a gel formulation has been developed 
for vaginal use. A multi-centre phase II 
trial of vaginal tenofovir gel is planned 
for 2005.
Non-nucleoside reverse transcriptase 
inhibitors (NNRTI) represent a range 
of chemical structures with direct 
binding to the active site of HIV-1, 
and efavirenz and nevirapine are very 
successful NNRTIs used in combination 
antiretroviral therapy. Some identiﬁ  ed 
NNRTIs are highly lipophilic, 
unsuitable for oral administration but 
potentially useful for intra-vaginal use 
as microbicides. Of these, UC781 and 
TMC120 are being formulated and 
developed as vaginal gels (Figure 1), 
with the aim of entering phase III trials 
in 2006 or 2007.
Finally, data have recently been 
reported on the prevention of 
simian-human immunodeﬁ  ciency 
virus transmission in the macaque 
vaginal challenge model by the use 
of monoclonal antibodies to HIV-1 
[17] and by a topical small-molecule 
CCR5 inhibitor, PSC-RANTES [18]. In 
both cases, the quantity of the agent 
required to prevent transmission in 
vivo was considerably greater than that 
required in vitro. The use of these 
highly speciﬁ  c agents in combination 
with other second- or third-generation 
microbicides may address this issue. 
However, monoclonal antibodies and 
peptides alone are never likely to meet 
the requirement for a microbicide to 
be cheaply manufactured. 
Phase III Trials of Vaginal 
Microbicides
Clinical trials of the efﬁ  cacy of 
microbicides present particular 
problems over and above those 
encountered for trials of preventative 
HIV vaccines. Trial populations must 
be identiﬁ  ed with an HIV incidence 
of at least 2% if sample size is to be 
feasible. However, this high level of 
HIV transmission must be vigorously 
addressed though counselling, 
screening for and treatment of sexually 
transmitted infections, and provision 
of condoms and health education. 
Adherence to use of the microbicide 
will be central to a successful outcome, 
and these agents will need to be used 
to protect every risky act of intercourse. 
As with male condoms, adherence 
is unlikely to be complete, and may 
reduce over time. Thus, trials designed 
to assess proof of efﬁ  cacy should be 
for as short an intervention period 
as possible in order not to dilute any 
antiviral effect of the microbicide 
through the likely reduction in 
adherence over time. 
Further, non-vaginal exposure to 
HIV such as through frequent anal 
intercourse or the use of non-sterile 
needles, will reduce the effect of 
a microbicide. Thus, considerable 
behavioural data will need to be 
collected at these phase III trials for 
the results to be fully interpreted and 
understood. These trials will therefore 
be large, requiring multiple sites in 
high-incidence regions, and they will be 
long in duration and hence expensive. 
Phase III trials of novel microbicide 
products undertaken in resource-poor 
regions in large numbers of women 
are ﬁ  nancially challenging, inevitably 
costing upwards of $US50 million 
depending on sample size. In the 
absence of commercial investment, this 
burden falls on the charitable and/or 
public sector. It is highly likely that 
because of the high costs, phase III trials 
will be the major rate-limiting step to 
new product development and testing.
In the long term, the effectiveness of 
microbicides will be highly dependent 
on continued high-level adherence, 
and this will need to examined in 
longer term trials As the safety and 
tolerability of these new materials 
will continue to be paramount, some 
participants even in shorter trials 
will need longer follow-up for safety. 
Ultimately, it is possible that adherence 
could be enhanced through novel 
depot methods for the sustained 
delivery of microbicides within the 
vagina without the need for dosing 
prior to each act of intercourse. For 
example, the development of resident 
vaginal rings allowing sustained slow 
release of the active agent over weeks 
or months would overcome the key 
issue of adherence. 
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Table 1. Status of Clinical Trials of Current Microbicide Compounds
Phase Number 
of Trials
Candidate Microbicide Organization/Developer 
III 4 PRO 2000 (naphthalene sulphonate) Microbicides Development Programme/
Indevus
Carraguard (carageenan) Population Council
Cellulose sulphate gel GMP
SAVVY/C-31G Family Health International/USAID/
Biosyn
II/IIb 2 BufferGel HIV Prevention Trials Netword/Reprotect
PRO 2000 HIV Prevention Trials Network/Indevus
II 3 Human monoclonal antibodies (C2F5, 
C2G12, C4E10)
Polymun Scientiﬁ  c
Protected lactobacilli in combination 
with BZK
Biofem
Tenofovir/PMPA gel Gilead Sciences
I/II 2 Invisible Condom Laval University
Praneem polyherbal Indian Council of Medical Research
I 6 Acidform/Amphora Global Microbicide Project
Cellulose acetate phthalate New York Blood Center/Lindsley F. 
Kimball Research Center
Lactin Vaginal capsule Osel
Polystyrene sulphate India National Institute of Pharmaceutical 
Education and Research
UC-781 Biosyn
VivaGel/SPL7013 Starpharma
 TMC120 International Partnership for 
Microbicides
Source: Alliance for Microbicide Development
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Advocacy, Funding, and 
Public–Private Partnerships
To date, there has been little interest 
from the pharmaceutical industry, 
outside of biotech companies, in the 
development of vaginal microbicides, 
and the burden of funding has fallen 
on the public and charitable sectors. 
This reliance on non-private funding 
has led to the new agents being 
developed in the academic sector, 
which has probably slowed progress 
even though the approach has 
been highly cost effective. However, 
microbicide research has attracted 
considerable political attention 
because of the urgency of the HIV 
epidemic, the plight of vulnerable 
women in high-incidence regions, 
and the delays in progress towards an 
HIV vaccine. A product-development 
public–private partnership has 
been established, the International 
Partnership for Microbicides, which 
is establishing clinical trial sites and is 
developing TMC120. Other advocacy 
groups include the Global Campaign 
for Microbicides and the Alliance 
for Microbicides, which ensure that 
pressure is maintained for funding 
the development of an effective 
microbicide.
Although it is hoped that one 
or more of the second-generation 
potential microbicides will have a 
positive risk–beneﬁ  t ratio, they may 
have only partial efﬁ  cacy, perhaps 
being as low as 35% effective. Indeed, 
the effect of these second-generation 
agents may be even lower when they 
are used outside of a clinical trial. 
Alternative approaches that require less 
attention and action from users—such 
as vaginal rings, more potent, longer 
acting products, or combinations of 
agents that might need to be used 
only once a day—could increase the 
effectiveness of microbicides and 
therefore have a much greater effect on 
HIV transmission. 
However, modelling suggests that 
even a microbicide shown to be only 
partially effective, if used by women 
in concert with the promotion of 
condoms for men, would have a 
beneﬁ  cial effect on the reduction of 
HIV transmission at a population level. 
In a sub-Saharan setting where endemic 
HIV prevalence is currently 10.8%, 
the introduction of a microbicide of 
50% efﬁ  cacy covering 50% of sex acts 
in high-risk women could achieve a 
population-wide reduction in HIV 
prevalence to 8.1% after 20 years.
Concurrent promotion of condoms 
additionally covering 50% of sex acts in 
high-risk men could potentially achieve 
a prevalence as low as 1.4% (see 
simulations; Table 2). In the continued 
absence of an effective HIV vaccine, a 
partially active microbicide would still 
be a highly desirable intervention.  
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Table 2. Modelling Microbicide Effectiveness 
Modelled
Microbicide Efﬁ  cacy
Modelled Microbicide Use Endemic HIV 
Prevalence 
(20 Years Later)
50% 50% of acts in high-risk women covered by microbicide 8.1%
50% of acts in all women covered by microbicide 6.4%
50% of acts in high-risk women covered by microbicide 
and 50% of acts in high-risk men covered by condom
1.4%
50% of acts in all women covered by microbicide and 
50% of acts in all men covered by condom
0.5%
75% 50% of acts in high-risk women covered by microbicide 6.8%
50% of acts in all women covered by microbicide 4.6%
50% of acts in high-risk women covered by microbicide 
and 50% of acts in high-risk men covered by condom
1.3%
50% of acts in all women covered by microbicide and 
50% of acts in all men covered by condom
0.5%
This table relates to a model of the future effect of a partially active microbicide on the HIV epidemic in a country with a current prevalence of 10.8%, and the 
additive effect of promoting concurrent condom use. It is assumed in simulations that condoms prevent both male to female and female to male infection 
while the microbicide is assumed to protect only the female. Condoms are assumed to have 95% efﬁ  cacy. 
DOI: 10.1371/journal.pmed.0020142.t002